Xencor (NASDAQ:XNCR) Hits New 12-Month Low - Should You Sell?

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) hit a new 52-week low during trading on Monday . The company traded as low as $10.55 and last traded at $10.81, with a volume of 165586 shares. The stock had previously closed at $11.23.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on XNCR. StockNews.com downgraded shares of Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. Wells Fargo & Company decreased their price objective on Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $34.38.

Xencor Price Performance

The company has a market capitalization of $612.31 million, a PE ratio of -2.72 and a beta of 0.90. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The company's 50 day moving average price is $14.73 and its 200-day moving average price is $19.78.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating analysts' consensus estimates of ($0.81) by $0.19. The firm had revenue of $52.79 million for the quarter, compared to analysts' expectations of $17.14 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. On average, sell-side analysts forecast that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Institutional Trading of Xencor

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in shares of Xencor by 5.5% in the 4th quarter. Vanguard Group Inc. now owns 8,017,366 shares of the biopharmaceutical company's stock valued at $184,239,000 after acquiring an additional 418,040 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Xencor by 2.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,036,412 shares of the biopharmaceutical company's stock worth $92,758,000 after buying an additional 107,350 shares during the period. Point72 Asset Management L.P. boosted its position in shares of Xencor by 147.3% in the third quarter. Point72 Asset Management L.P. now owns 3,120,229 shares of the biopharmaceutical company's stock worth $62,748,000 after buying an additional 1,858,440 shares during the period. TCG Crossover Management LLC grew its stake in shares of Xencor by 1.0% in the fourth quarter. TCG Crossover Management LLC now owns 2,452,138 shares of the biopharmaceutical company's stock valued at $56,350,000 after buying an additional 25,000 shares in the last quarter. Finally, RTW Investments LP raised its holdings in shares of Xencor by 317.9% during the 4th quarter. RTW Investments LP now owns 2,402,883 shares of the biopharmaceutical company's stock valued at $55,218,000 after buying an additional 1,827,883 shares during the period.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.